Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study.
Alessandro RussoMarco RussanoTindara FranchinaMaria R MigliorinoGiuseppe AprileGiovanni MansuetoAlfredo BerrutiAlfredo FalconeMichele AietaAlain GelibterAntonio RussoSandro BarniMichele MaioOlga MartelliFrancesco PantanoDaniela IaconoLorenzo CalvettiSilvia QuadriniElisa RocaEnrico VasileMarco ImperatoriMario OcchipintiAntonio GalvanoFausto PetrelliLuana CalabròGiulia PasquiniSalvatore IntagliataGiuseppina R R RicciardiGiuseppe ToniniDaniele SantiniVincenzo AdamoPublished in: Advances in therapy (2020)
Patients with pretreated NSCLC and high pretreatment levels of NLR and PLR may experience inferior outcomes with nivolumab. Therefore, in this subgroup of patients with poor prognosis the use of alternative therapeutic strategies may be a valuable option, especially in programmed cell death ligand 1 (PD-L1)-negative patients and/or in the presence of other additional poor prognostic factors.